Skip to main content
main-content

medwireNews@ESMO2017

Conference commentaries

04-10-2017 | ESMO 2017 | Video

Genitourinary cancer highlights from ESMO 2017

ESMO expert Rodrigo Dienstmann comments on the findings of the RANGE and CheckMate 214 trials, presented at the second Presidential symposium at the ESMO 2017 Congress in Madrid, Spain.

Read the accompanying news stories on the RANGE and CheckMate 214 trials.

02-10-2017 | ESMO 2017 | Video

Expert commentary: MONARCH 3 trial

ESMO expert Rodrigo Dienstmann discusses the MONARCH 3 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to aromatase inhibitor therapy in women with advanced hormone receptor-positive, HER2-negative breast cancer.

Click here for the accompanying news story.

29-09-2017 | ESMO 2017 | Video

Highlights of the ESMO 2017 lung cancer program

Advisory Board member Lecia Sequist chooses her top picks of the lung cancer oral abstracts and posters presented at the ESMO 2017 Congress, and touches upon those she’s looking forward to at future meetings.

26-09-2017 | ESMO 2017 | Video

ESMO 2017: BRIM8 trial findings

Presenter Karl Lewis outlines the findings for adjuvant vemurafenib versus placebo in patients at high risk of recurrence after resection of BRAF V600+ advanced or metastatic melanoma.

26-09-2017 | ESMO 2017 | Video

ESMO 2017: Concomitant chemotherapy remains optimal strategy for locally advanced cervical cancer

Surgeon and study author Amita Maheshwari discusses the outcomes of a neoadjuvant chemotherapy approach to locally advanced squamous carcinoma of the cervix.

Read the accompanying news story here.

26-09-2017 | ESMO 2017 | Video

ESMO 2017: Unmet needs in lung cancer patients

Advisory Board member Fiona Blackhall highlights key studies regarding unmet needs in lung cancer patients at the ESMO 2017 Congress. 

25-09-2017 | ESMO 2017 | Video

ESMO 2017: RANGE trial results

Daniel Petrylak outlines the RANGE trial results for use of ramucirumab in patients with advanced urothelial carcinoma.

Read the accompanying news story.

25-09-2017 | ESMO 2017 | Video

Durvalumab: A new option for stage III NSCLC patients?

Study co-author Davey Daniel reviews the findings of the phase III PACIFIC trial investigating ​​​​​​​durvalumab in patients with locally advanced, unresectable NSCLC.

Read the related story here.

20-09-2017 | ESMO 2017 | Video

ESMO 2017: Melanoma highlights

ESMO Melanoma Faculty Coordinator Olivier Michielin discusses the CheckMate 238, COMBI-AD, and BRIM8 trials presented at the third Presidential symposium.

Read the related news stories on the CheckMate 238 and COMBI-AD trials.

15-09-2017 | ESMO 2017 | Video

NSCLC highlights from ESMO 2017

ESMO expert Floriana Morgillo provides independent comment on the PACIFIC, FLAURA, and IFCT-0302 trials, the focus of the first Presidential symposium.

Read the related news stories on the PACIFIC, FLAURA, and IFCT-0302 results.

15-09-2017 | ESMO 2017 | Video

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC

Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.

Read the related news story here.

14-09-2017 | ESMO 2017 | Video

CT timing questioned for patients after complete NSCLC resection

Virginie Westeel explains the results of the phase III IFCT-0302 trial examining the benefit of CT imaging in NSCLC patients who have undergone complete resection.

Read the related news story here.

Research news

29-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017

ALUR, ALEX results cement alectinib as advanced ALK-positive NSCLC standard of care

The findings of the ALUR trial and of an additional analysis of the ALEX trial confirm the benefits of treatment with the second-generation anaplastic lymphoma kinase inhibitor alectinib in patients with advanced ALK-positive non-small-cell lung cancer.

29-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017 in brief

Hyperprogression not uncommon after immunotherapy in NSCLC patients

Hyperprogression can occur following treatment with agents targeting programmed cell death protein 1 or its ligand, shows a review of patients with advanced non-small-cell lung cancer.

27-09-2017 | Small cell lung cancer | ESMO 2017 | News

ESMO 2017

Preliminary lurbinectedin results ‘remarkable’ for relapsed SCLC

Lurbinectedin has potential for the treatment of patients with relapsed small-cell lung cancer as a single agent or in combination with another chemotherapy drug, suggests research reported at the ESMO 2017 Congress in Madrid, Spain.

25-09-2017 | Gastric cancer | ESMO 2017 | News

ESMO 2017 in brief

FLOT4-AIO results could guide operable gastric cancer treatment

Perioperative docetaxel, oxaliplatin, and 5-fluorouracil/leucovorin treatment should be a new standard of care for patients with operable adenocarcinoma of the stomach or gastroesophageal junction, say the FLOT4-AIO trial investigators.

20-09-2017 | Epidemiology | ESMO 2017 | News

ESMO 2017 in brief

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

19-09-2017 | Risk factors | ESMO 2017 | News

ESMO 2017 in brief

Abdominal fat linked to elevated cancer risk

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.

Poster highlights

29-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017 in brief

Hyperprogression not uncommon after immunotherapy in NSCLC patients

Hyperprogression can occur following treatment with agents targeting programmed cell death protein 1 or its ligand, shows a review of patients with advanced non-small-cell lung cancer.

20-09-2017 | Epidemiology | ESMO 2017 | News

ESMO 2017 in brief

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

19-09-2017 | Risk factors | ESMO 2017 | News

ESMO 2017 in brief

Abdominal fat linked to elevated cancer risk

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.

image credits